El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...

Research backs this up: Young men who consumed more protein while losing weight and on an intense exercise regiment gained ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

I had been taking Zepbound for about six months when it clicked. My period — the monster that turned me from a functioning ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

We’re not going to stay in our box,” said John Bolla, president of UPS Healthcare. “We can do something different, and we can ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...